The Claim

Among Medicare Advantage beneficiaries with type 2 diabetes, initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus sodium-glucose cotransporter-2 inhibitors (SGLT2i) is not associated with a statistically significant difference in all-cause hospitalizations, diabetes-related hospitalizations, or emergency department visits over a 12-month period.

Source: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
67score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

Among Medicare Advantage patients with type 2 diabetes, starting a GLP-1 RA medication or an SGLT2i medication results in the same rate of hospital visits and emergency department visits over 12 months.

See the scientific wording

In Medicare Advantage beneficiaries with type 2 diabetes, there is no significant difference in all-cause or diabetes-related hospitalizations or emergency department visits over 12 months between those initiating glucagon-like peptide-1 receptor agonists (GLP-1 RA) and those initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i), suggesting comparable acute care utilization despite differing drug profiles.

Why this might work

Both drugs lower blood sugar and stabilize metabolism, so the body avoids the severe spikes and crashes that trigger hospital visits. This keeps people out of the hospital and emergency rooms, no matter which drug they start.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

    For older adults with type 2 diabetes, starting either a GLP-1 RA or an SGLT2i drug leads to about the same number of hospital stays and emergency room visits over a year — even though one is more expensive. The study found no difference in how often people went to the hospital or ER.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.